Real World Data on Vedolizumab Concentration and Outcomes in Inflammatory Bowel Disease (IBD) Patients Switching From Intravenous (IV) to Subcutaneous (SC) Vedolizumab in University Hospital Center Osijek

NCT05504915 · clinicaltrials.gov ↗

COMPLETED

Status

31

Enrollment

OTHER

Sponsor class

Conditions

Inflammatory Bowel Diseases
Crohn Disease
Colitis, Ulcerative

Sponsor

Osijek University Hospital

Collaborators

[object Object]